NEW YORK (GenomeWeb News) – Quest Diagnostics today reported that its second-quarter revenues declined 3 percent year over year, as the diagnostics information services firm missed Wall Street estimates on the top and bottom line.

Quest had revenues of $1.82 billion for the three months ended June 30, compared to $1.88 billion for Q2 2012. It fell short of the consensus analysts' estimate of $1.84 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.